May. 28 at 11:01 AM
$GALT Its true that GALT's CMO is well connnected. &in contrast to several yrs ago, the KOLs now appear to be promoting Belapectin's value, and we have 4 publications. Clearly there is momentum heading into the FDA meeting, and BTD is in play. But what my fellow Bulls fail to consider is that the FDA behaves like its own organism. There is a trail of tears for drugs that left sponsors shaking their heads. Every morning, one reads a letter in the WSJ about some promising drug or device that despite a body of evidence was delayed or rejected by the agency. The intent is not to create FUD. This poster owns a lot of shares, but I work on probabilities, not hopium. I have repeatedely said, hope I am wrong on my cautionary notes, but have too many times seen the FDA make decisions that leave stakeholders in the dust. Maintain that AA will not be granted, that BTD has a chance, and that AA pathway will be defined. That clarity would be a win, and should trigger BP interest. Opinion only.
